Latest BioArctic News & Updates

See the latest news and media coverage for BioArctic. We track all announcements, press releases, and industry mentions in real time, all in one place.

BioArctic

Research-oriented biopharma company for neurodegenerative diseases

bioarctic.com

Headquarters: Stockholm, Sweden
Founded year: 2003
Company type: Public company
Number of employees: 150–200

Last updated Today

Latest news about BioArctic

In short: BioArctic achieved record 2025 financial results and advanced its Alzheimer's drug Leqembi through multiple global regulatory approvals and sales.

Company announcements

Yesterday BioArctic

BioArctic and Lilly sign research and collaboration agreement

BioArctic receives USD 30 million upfront with up to USD 770 million in milestones for combining its BrainTransporter with a Lilly drug candidate.

May 29 BioArctic

BioArctic issued 5,000 Class B shares for stock option exercise

Total shares are 88,724,485 with 218,324,449 votes.

May 28 BioArctic

BioArctic AGM approved dividend and re-elected board

Dividend of SEK 2 per share, re-elected board members, and new incentive program introduced.

May 20 BioArctic

BioArctic reports strong Q1 2026 financials with Leqembi milestone

Net revenues SEK 437.6M, operating profit SEK 210.8M, and a EUR 20M milestone payment from Eisai.

Media coverage

Yesterday Life Science Sweden

Bioarctic in billion-dollar agreement with Lilly about Braintransporter

Bioarctic has secured yet another agreement for Braintransporter. Now Eli Lilly will use the technology in the development of new treatments for neurodegenerative diseases.

Yesterday Yahoo Finance

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology

BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company...

May 27 Life Science Sweden

Bioarctic praised after successes with Leqembi

"This will become Sweden's leading pharmaceutical company," says co-founder Lars Lannfelt. Now Bioarctic wins the award SvD Business Achievement 2026.

May 25 Yahoo Finance

BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi. According to Eisai's...

Never miss news about BioArctic

Track BioArctic and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BioArctic competitors & trending companies

Browse news for competitors to BioArctic and other trending companies.